Literature DB >> 8522492

The immunopathogenesis of cutaneous T-cell lymphoma.

A H Rook1, P Heald.   

Abstract

A perplexing array of immune abnormalities have been described in cutaneous T-cell lymphoma. This article discusses the mechanisms underlying these immune abnormalities. The immune processes that have become disordered are examined with reference to the steps involved in generating the disease and how these steps can be corrected therapeutically.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8522492

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  11 in total

1.  Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

Authors:  Rachael A Clark; Rei Watanabe; Jessica E Teague; Christoph Schlapbach; Marianne C Tawa; Natalie Adams; Andrew A Dorosario; Keri S Chaney; Corey S Cutler; Nicole R Leboeuf; Joi B Carter; David C Fisher; Thomas S Kupper
Journal:  Sci Transl Med       Date:  2012-01-18       Impact factor: 17.956

Review 2.  Menus for managing patients with cutaneous T-cell lymphoma.

Authors:  Brian Poligone; Peter Heald
Journal:  Semin Cutan Med Surg       Date:  2012-03

3.  Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death.

Authors:  Paula V Cabrera; Maho Amano; Junya Mitoma; Jessica Chan; Jonathan Said; Minoru Fukuda; Linda G Baum
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

Review 4.  Targeting selectins and selectin ligands in inflammation and cancer.

Authors:  Steven R Barthel; Jacyln D Gavino; Leyla Descheny; Charles J Dimitroff
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

Review 5.  Cutaneous T-cell lymphoma/leukemia.

Authors:  R S Siegel; T M Kuzel
Journal:  Curr Treat Options Oncol       Date:  2000-04

6.  Profile of differentially expressed Toll-like receptor signaling genes in the natural killer cells of patients with Sézary syndrome.

Authors:  Kelly C G ManfrereC; Marina P Torrealba; Denis R Miyashiro; Nátalli Z Pereira; Fabio S Y Yoshikawa; Luana de M Oliveira; Jade Cury-Martins; Alberto J S Duarte; José A Sanches; Maria N Sato
Journal:  Oncotarget       Date:  2017-09-18

7.  TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.

Authors:  Emmanuella Guenova; Rei Watanabe; Jessica E Teague; Jennifer A Desimone; Ying Jiang; Mitra Dowlatshahi; Christoph Schlapbach; Knut Schaekel; Alain H Rook; Marianne Tawa; David C Fisher; Thomas S Kupper; Rachael A Clark
Journal:  Clin Cancer Res       Date:  2013-06-19       Impact factor: 12.531

Review 8.  The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.

Authors:  David M Weiner; Joseph S Durgin; Maria Wysocka; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2020-12-22       Impact factor: 11.527

9.  Toll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sézary syndrome.

Authors:  Kelly C G Manfrere; Marina P Torrealba; Denis R Miyashiro; Luanda M S Oliveira; Gabriel C de Carvalho; Josenilson F Lima; Anna Claudia C C Branco; Nátalli Z Pereira; Juliana Pereira; José A Sanches; Maria N Sato
Journal:  Oncotarget       Date:  2016-11-15

Review 10.  Therapy for mycosis fungoides.

Authors:  Jeanette Lundin; Anders Osterborg
Journal:  Curr Treat Options Oncol       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.